Holding(s) in Company
December 24, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Shire Plc JE00B2QKY057 | ||||||||||||||||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | |||||||||||||||||||
| Non-UK issuer | X | ||||||||||||||||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | |||||||||||||||||||
| An acquisition or disposal of voting rights | X | ||||||||||||||||||
| An acquisition or disposal of financial instruments | |||||||||||||||||||
| An event changing the breakdown of voting rights | |||||||||||||||||||
| Other (please specify)iii: | |||||||||||||||||||
| 3. Details of person subject to the notification obligationiv | |||||||||||||||||||
| Name | UBS Investment Bank UBS Group AG | ||||||||||||||||||
| City and country of registered office (if applicable) | Zürich Switzerland | ||||||||||||||||||
| 4. Full name of shareholder(s) (if different from 3.)v | |||||||||||||||||||
| Name | UBS AG London Branch | ||||||||||||||||||
| City and country of registered office (if applicable) | London, United Kingdom | ||||||||||||||||||
| 5. Date on which the threshold was crossed or reachedvi: | 20 December 2018 | ||||||||||||||||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 21 December 2018 | ||||||||||||||||||
| 7. Total positions of person(s) subject to the notification obligation | |||||||||||||||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii | ||||||||||||||||
| Resulting situation on the date on which threshold was crossed or reached | 3.55 | % | 2.25 | % | 5.80 | % | 917,104,410 | ||||||||||||
| Position of previous notification (if applicable) | 3.74 | % | 2.26 | % | 6.01 | % | |||||||||||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||||||||||||
| A: Voting rights attached to shares | |||||||||||||||||||
| Class/type of shares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||||||||||||
| Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||||||||||||
| JE00B2QKY057 | 32'567'127 | 3.55 | % | ||||||||||||||||
| SUBTOTAL 8. A | 32'567'127 | 3.55 | % | ||||||||||||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||||||||||||
| Type of financial instrument | Expiration datex | Exercise/ Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||||||||||||
| Right to recall lent ADRs (US82481R1068) | Anytime | 1'807'932 | 0.20 | % | |||||||||||||||
| US82481R1068 | 16'848'144 | 1.84 | % | ||||||||||||||||
| Physically settled Long Call Options | 21/12/2018 to 18/04/2019 | 1'083'000 | 0.12 | % | |||||||||||||||
| SUBTOTAL 8. B 1 | 19'739'076 | 2.15 | % | ||||||||||||||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||||||||||||
| Type of financial instrument | Expiration datex | Exercise/ Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||||||||||||
| Short Put Options | 21/12/2018 to 18/01/2019 | Physical | 928'800 | 0.10 | % | ||||||||||||||
| SUBTOTAL 8.B.2 | 928'800 | 0.10 | % | ||||||||||||||||
| 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) | ||||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | ||||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | X | |||||
| Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |||
| UBS Group AG | ||||||
| UBS AG | ||||||
| UBS AG London Branch | 3.47 | % | 5.72 | % | ||
| UBS Group AG | ||||||
| UBS AG | ||||||
| UBS Limited | ||||||
| UBS Group AG | ||||||
| UBS AG | ||||||
| UBS Switzerland AG | ||||||
| UBS Group AG | ||||||
| UBS AG | ||||||
| UBS Americas Holding LLC | ||||||
| UBS Americas Inc. | ||||||
| UBS Securities LLC | ||||||
| | |
| 10. In case of proxy voting, please identify: | |
| Name of the proxy holder | |
| The number and % of voting rights held | |
| The date until which the voting rights will be held | |
| 11. Additional informationxvi | |
| Place of completion | Opfikon, Switzerland |
| Date of completion | 21.12.2018 |
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | christoph.brackmann@shire.com | +41 41 288 41 29 |
| Sun Kim | sun.kim@shire.com | +1 617 588 8175 |
| Scott Burrows | scott.burrows@shire.com | +41 41 288 4195 |
| Media | ||
| Katie Joyce | kjoyce@shire.com | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.